Halozyme Therapeutics (HALO) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Halozyme Therapeutics, as the data feed reports them.

Analysts' mean target, 9 analysts
$119.89
24.9% above the price

The 9 analysts reported by the data feed have a mean price target for Halozyme Therapeutics of $119.89, 24.9% above the $95.97 price (range $79.00–$149.00). 15.69% of the float was sold short as of Oct 30, 2026. Institutions hold 115.5% of the shares and insiders 1.1%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$119.89+24.9% vs price
Analysts
9
Short interest
15.69%of float, Oct 30, 2026
Short ratio
6.19 days
Institutions
115.5%
Insiders
1.08%
Beta
0.9

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

9 analysts covering Halozyme Therapeutics, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $95.97.

Analysts' price targets for Halozyme Therapeutics
Mean price target$119.8924.9% above the price (+24.9%)
Median price target$125.0030.2% above the price (+30.2%)
Highest target$149.0055.3% above the price (+55.3%)
Lowest target$79.0017.7% below the price (−17.7%)
Analysts with a target9

Ratings this month · 9 analysts

Strong buy 1(11%)Buy 4(44%)Hold 4(44%)
Analysts' ratings of Halozyme Therapeutics this month, by rating
RatingAnalystsShare
Strong buy111%
Buy444%
Hold444%
Sell00%
Strong sell00%

The feed averages these to 2 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “buy”.

Who owns Halozyme Therapeutics

Ownership of Halozyme Therapeutics
Held by institutions115.5%1,022 institutions; percent of shares outstanding
Held by institutions, of the float116.7%
Held by insiders1.08%percent of shares outstanding
Shares outstanding114.01M
Float112.7Mshares available to trade
Insiders' net purchases, six months−13.88K10 purchases (309.22K shares), 11 sales (323.1K shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Halozyme Therapeutics
Shares short13.65Mas of Oct 30, 2026
Percent of float15.69%shares short ÷ float
Percent of shares outstanding11.98%shares short ÷ shares outstanding
Short ratio (days to cover)6.19shares short ÷ average daily volume

Halozyme Therapeutics short interest from FINRA, with its history

Trading figures

Trading figures for Halozyme Therapeutics
Beta0.9movement against the market; 1 moves with it
52-week high$134.00
52-week low$61.23
Average volume, 3 months2.25Mshares a day
Average volume, 10 days2.56Mshares a day

Questions and answers

What is the analysts' price target for Halozyme Therapeutics (HALO)?

As reported by the data feed, the mean price target of the 9 analysts covering Halozyme Therapeutics is $119.89, 24.9% above the latest price of $95.97. The highest target is $149.00 and the lowest $79.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Halozyme Therapeutics stock?

Of the 9 ratings the data feed reports for the current month, 1 are strong buy, 4 buy, 4 hold, 0 sell and 0 strong sell.

How many Halozyme Therapeutics shares are sold short?

As reported by the data feed, 13.65M shares were sold short, 15.69% of the float as of Oct 30, 2026. At the average daily volume that is 6.19 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Halozyme Therapeutics stock?

As reported by the data feed, institutions hold 115.5% of the shares (1,022 institutions) and insiders 1.1%. There are 114.01M shares outstanding, of which 112.7M are in the float.

How much does Halozyme Therapeutics stock move with the market?

Its beta, as reported by the data feed, is 0.9: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $61.23 and $134.00.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) statistics and analyst targets”, data as of 17 November 2026. https://funkfolio.com/stock/HALO/statistics

Underlying data: Yahoo Finance.